Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores

BMC Research Notes

Chau-Ting Yeh²  Kuo-Chien Tsao³  Shiu-Feng Huang¹  Kung-Hao Liang²  Chao-Wei Hsu² 

[1] Department of Pathology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan;Liver Research Center, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan;Departments of Laboratory Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan

关键词: Receiver operation characteristic curve;    Score;    Fibrosis;    Hepatitis B;   

Others  :  1142594
DOI  :  10.1186/1756-0500-6-212

 received in 2012-12-27, accepted in 2013-05-23,  发布年份 2013

【 摘 要 】

Background

Despite the availability of patented non-invasive methods, evaluation of the degrees of liver fibrosis remains difficult when conducting a retrospective study. Such inadequacy is largely caused by requirement of biochemical parameters rarely performed in routine clinical tests. We developed a novel fibrosis HB-F score using commonly performed tests for HBV infected patients.

Methods

424 patients with chronic HBV infection were included. Using clinical and virological data, HB-F score was developed from a training cohort (n = 213) and validated in a separate cohort (n = 211). The performance was compared with five other unpatented scores using ROC curves.

Results

Univariate and multivariate analysis revealed that age, AST/ALT ratio, platelet count and prothrombin time prolongation were significantly associated with the ISHAK fibrosis score, and were used to calculate the HB-F score. When HB-F was used to assess prominent fibrosis and cirrhosis, the AUC was 0.81 and 0.80 respectively in the training cohort, and 0.80 and 0.76 respectively in the validation cohort. HB-F had the highest AUC compared with other scores. Furthermore, in assessing paired liver biopsies with increase or decrease of ISHAK scores, HB-F showed significant change in the same direction.

Conclusions

A new non-invasive score was developed, which could be used to assess severity of liver fibrosis in retrospective longitudinal studies in HBV patients.

【 授权许可】

   
2013 Hsu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
• [2]Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 41:1046-1055.
• [3]Ishak K, Baptista A, Bianchi L: Histologic grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
• [4]Knodell RG, Ishak KG, Black WC: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435.
• [5]Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996, 24:289-293.
• [6]Liaw YF, Sung JJ, Chow WC: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
• [7]Goodman ZD: Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007, 47:598-607.
• [8]Ferrailoi G, Tinelli C, Malfitano A: Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosisi in chronic hepatitis C. Am J Roentgenol 2012, 199:19-25.
• [9]Kim SU, Lee JH, Kim Do Y: Prediction of liver–related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012, 7:e36676.
• [10]Yoon KT, Lim SM, Park JY: Liver stiffiness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci 2012, 57:1682-1691.
• [11]Cardoso AC, Carvalho-Filho RJ, Stern C: Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012, 32:612-621.
• [12]Williams AL, Hoofnagle JH: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology 1988, 95:734-739.
• [13]Wai CT, Greenson JK, Fontana RJ: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
• [14]Ohta T, Sakaguchi K, Fujiwara A: Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006, 60:77-84.
• [15]Koda M, Matunaga Y, Kawakami M: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297-306.
• [16]Sterling RK, Lissen E, Clumeck N: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
• [17]Vallet-Pichard A, Mallet V, Nalpas B: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology 2007, 46:32-36.
• [18]Poynard T, Ngo Y, Munteanu M: Biomarkers of liver injury for hepatitis clinical trial: a meta-analysis of longitudinal studies. Antivir Ther 2010, 15:617-631.
• [19]Stibbe KJ, Verveer C, Francke J: Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroentero 2011, 46:962-972.
• [20]Poynard T, Ngo Y, Munteanu M: Noninvasive markers of hepatitis fibrosis in chronic hepatitis B. Curr Hepat Rep 2011, 10:87-97.
• [21]Kim BK, Kim SU, Kim HS: Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One 2012, 7:e35825.